Ravi joined SV as a Venture Partner in 2022 and is the Chief Medical Officer for the SV-created Sitryx Therapeutics.
Ravi has over 25 years' experience in academic medicine and the biopharmaceutical industry, leading multiple different programmes across a range of therapeutic areas and treatment modalities in discovery, early and late-stage development.
Prior to joining SV, Ravi was Head of R&D and Chief Medical Officer at Swedish Orphan Biovitrum and previously held roles as Chief Medical Officer at Aeglea Biotherapeutics; Vice President, Head of Immunology Clinical Development at GlaxoSmithKline; Group Medical Director, Immunology at Roche Genentech. His career began as a physician scientist and he was a Senior Lecturer and Consultant Rheumatologist at the Hammersmith Hospital, Imperial College, London.
Outside of SV, Ravi is also an independent director of DBV Technologies and Chief Medical Officer at Oxford Biomedica.
MA and MBBCh from the University of Cambridge; PhD Imperial College, London, MFPM.